JP2021509414A5 - - Google Patents
Info
- Publication number
- JP2021509414A5 JP2021509414A5 JP2020555742A JP2020555742A JP2021509414A5 JP 2021509414 A5 JP2021509414 A5 JP 2021509414A5 JP 2020555742 A JP2020555742 A JP 2020555742A JP 2020555742 A JP2020555742 A JP 2020555742A JP 2021509414 A5 JP2021509414 A5 JP 2021509414A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- inhibitors
- pharmaceutical composition
- leukemia
- isotope
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862612926P | 2018-01-02 | 2018-01-02 | |
| US62/612,926 | 2018-01-02 | ||
| PCT/US2018/068102 WO2019136016A1 (en) | 2018-01-02 | 2018-12-31 | Isotopologues of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021509414A JP2021509414A (ja) | 2021-03-25 |
| JPWO2019136016A5 JPWO2019136016A5 (https=) | 2022-01-17 |
| JP2021509414A5 true JP2021509414A5 (https=) | 2022-01-17 |
| JP7357637B2 JP7357637B2 (ja) | 2023-10-06 |
Family
ID=67143955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555742A Active JP7357637B2 (ja) | 2018-01-02 | 2018-12-31 | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドの同位体置換体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210069356A1 (https=) |
| EP (1) | EP3735243A4 (https=) |
| JP (1) | JP7357637B2 (https=) |
| KR (1) | KR20200105662A (https=) |
| CN (1) | CN111542321A (https=) |
| WO (1) | WO2019136016A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435128B2 (en) | 2017-05-31 | 2025-10-07 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| JP2022554346A (ja) | 2019-11-05 | 2022-12-28 | セルジーン コーポレーション | ２－（４－クロロフェニル）－ｎ－（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル）メチル）－２，２－ジフルオロアセトアミドとの併用療法 |
| MX2022005812A (es) | 2019-11-13 | 2022-08-16 | Taiho Pharmaceutical Co Ltd | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
| AU2020396543A1 (en) * | 2019-12-06 | 2022-06-16 | Celgene Corporation | Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CN113149801A (zh) * | 2021-01-27 | 2021-07-23 | 南京工业大学 | 氘代多卤素芳香族化合物及其制备方法、有机中间体 |
| CN113125602A (zh) * | 2021-04-16 | 2021-07-16 | 山东铂源药业有限公司 | 一种哌柏西利中残留溶剂的检测方法 |
| BR112023025403A2 (pt) | 2021-06-25 | 2024-02-20 | Korea Res Inst Chemical Tech | Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo |
| WO2023274246A1 (zh) * | 2021-06-28 | 2023-01-05 | 成都分迪药业有限公司 | 酰胺类化合物及其用途 |
| EP4680597A1 (en) * | 2023-03-13 | 2026-01-21 | The Johns Hopkins University | Nonsense mediated decay inhibitor compounds |
| US20250368620A1 (en) * | 2024-05-30 | 2025-12-04 | Celgene Corporation | ARNT Degrading Compounds and Uses Thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9695145B2 (en) * | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| CN105246480A (zh) * | 2013-04-02 | 2016-01-13 | 细胞基因公司 | 使用4-氨基-2-(2,6-二氧代-哌啶-3-基)-异吲哚啉-1,3-二酮治疗和控制中枢神经系统癌症的方法和组合物 |
| TW201540323A (zh) * | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| EP3399981B1 (en) * | 2016-01-08 | 2023-08-02 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
-
2018
- 2018-12-31 WO PCT/US2018/068102 patent/WO2019136016A1/en not_active Ceased
- 2018-12-31 JP JP2020555742A patent/JP7357637B2/ja active Active
- 2018-12-31 CN CN201880085364.0A patent/CN111542321A/zh active Pending
- 2018-12-31 US US16/959,560 patent/US20210069356A1/en not_active Abandoned
- 2018-12-31 KR KR1020207018913A patent/KR20200105662A/ko not_active Withdrawn
- 2018-12-31 EP EP18898451.2A patent/EP3735243A4/en not_active Withdrawn